cms.bioaccessla.com

Tag: first-in-human

  • INVIMA-Ready MedTech Dossier Checklist for First-in-Human Studies in Colombia

    INVIMA-Ready MedTech Dossier Checklist for First-in-Human Studies in Colombia

    For a leading MedTech startup, Colombia can be an attractive setting for a first-in-human or early-feasibility study. The opportunity, however, is not created by a single form or approval letter. It depends on whether the sponsor presents a coherent story about intended use, risk, clinical need, participant protection, and operational control.

    An INVIMA-ready dossier is therefore more than a document folder. It is a cross-functional quality system that allows the regulator, ethics committee, investigators, and import team to reach the same conclusion from the same evidence. The following checklist is designed for sponsors preparing an early-stage medical device study in Colombia. Requirements can change, so the current INVIMA forms and instructions should always be confirmed before filing.

    1. Start with the intended use and risk story

    The first quality gate is a short, precise statement of what the device is intended to do in the study and what the study is not designed to prove. Define the target population, clinical setting, operator, use procedure, expected benefit, and foreseeable hazards. Then connect each claim to a source of evidence.

    This discipline prevents a common early-stage problem: the protocol describes a feasibility objective, while the technical file reads like a marketing submission. A first-in-human dossier should be candid about uncertainty and show how the investigation will manage it.

    • Define the study purpose: distinguish feasibility, initial safety, usability, and exploratory performance objectives.
    • Map the risk profile: link hazards and mitigations to the risk-management file and to monitoring activities.
    • Clarify the use environment: describe the procedure, training assumptions, accessories, maintenance, and conditions that could affect performance.
    • Identify evidence gaps: explain which questions require clinical data because bench testing, literature, or comparable-device information is insufficient.

    2. Build the Colombia-specific submission core

    INVIMA’s clinical-investigation resources identify the GICASE group and publish current forms and checklists for medical-device studies. The page references Resolution 8430 of 1993 as the general framework for research involving human beings and lists a checklist for technical-concept requests involving prototype medical-device protocols and associated documents. Sponsors should use the current version of that checklist as the filing backbone rather than relying on a generic global template.

    The dossier should be assembled as a controlled set of modules, with an index that makes review easy:

    • Protocol and synopsis: objectives, design, population, eligibility criteria, endpoints, follow-up, stopping rules, statistical rationale, and deviation handling.
    • Device and technical file: description, intended use, design overview, manufacturing controls, verification and validation results, software or electrical documentation where relevant, labeling, instructions for use, and traceability.
    • Risk and clinical justification: risk analysis, residual-risk assessment, literature or comparable-device evidence, known limitations, and a clear explanation of why the proposed study is proportionate to the remaining uncertainty.
    • Participant protection: informed-consent materials, participant information, privacy safeguards, compensation or treatment arrangements, insurance documentation where applicable, and safety-reporting procedures.
    • Site and investigator package: qualifications, facilities, equipment, training, delegation, recruitment plan, monitoring approach, and the ethics committee pathway.

    Use a document matrix to show where each requirement is answered. If a requirement is not applicable, state why and identify the supporting rationale. An unexplained blank looks like an omission; a documented rationale shows control.

    3. Treat ethics, imports, and site readiness as one workstream

    Regulatory submission is only one part of activation. A technically complete dossier can still lose time if the ethics committee receives a different protocol version, the site is not trained on the final instructions, or the investigational shipment cannot be cleared. Sponsors should manage these dependencies in a single readiness plan.

    • Synchronize versions: the protocol, consent form, investigator materials, labels, and training deck should use the same device description, risks, endpoints, and amendment status.
    • Prepare the ethics package early: confirm committee submission windows, local language needs, investigator signatures, participant-facing readability, and the process for reporting serious adverse events.
    • Plan import readiness: confirm the responsible local party, customs documentation, product classification, declared value, packing list, serial or lot traceability, storage conditions, and return or destruction process.
    • Test site execution: rehearse device receipt, quarantine, accountability, calibration or setup, troubleshooting, use, cleaning, and post-procedure documentation before the first participant visit.

    This approach also improves responses to information requests. When a reviewer asks how a risk is controlled, the sponsor can point to the same control in the technical file, protocol, training record, and monitoring plan.

    4. Run a sponsor-side quality-control gate

    Before filing, conduct a structured review that is independent of the person who assembled the first draft. The goal is not to make the dossier longer. It is to eliminate contradictions that create avoidable clarification cycles.

    • Compare the device name used internally with the generic description used in participant materials and shipment documents.
    • Reconcile every primary and secondary endpoint with the analysis plan, case-report forms, and monitoring metrics.
    • Check that every residual risk has a mitigation, a participant-facing disclosure, and a safety signal or escalation pathway.
    • Verify that investigator responsibilities, sponsor responsibilities, and vendor responsibilities are explicit.
    • Confirm that translations preserve technical meaning and that the controlled English master is traceable.
    • Prepare a response log with an owner, due date, evidence reference, and final approval for each question.

    The best dossier is not the one with the most pages. It is the one a reviewer can navigate quickly, understand without inference, and assess against the study’s actual risk. For a leading MedTech startup, that clarity is a competitive operational advantage: it protects participant safety while reducing rework across regulatory, ethics, clinical, and logistics teams.

    FAQ: INVIMA-ready MedTech dossiers

    Does a global clinical-investigation package need a Colombia-specific adaptation?

    Yes. A global core can reduce duplication, but the sponsor still needs a Colombia-specific regulatory and ethics annex. Adapt the local forms, language, responsible parties, participant materials, import plan, and explanations of how foreign evidence applies to the Colombian setting.

    When should import planning begin?

    Begin during protocol and site planning, not after approval. Classification, local responsibility, documentation, storage, and return or destruction decisions can affect the feasibility of the study and should be reflected in the operational plan.

    What is the most common avoidable dossier weakness?

    Inconsistency. Differences in device description, endpoint definitions, risk language, document versions, or responsibilities create questions that are preventable with a cross-document matrix and an independent quality-control review.

  • A Practical Regulatory Timeline For First-In-Human Medical Device Studies In Latin America (2026)

    A Practical Regulatory Timeline for First-in-Human Medical Device Studies in Latin America (2026)

    For MedTech founders and regulatory directors, Latin America can be the fastest path to a first-in-human (FIH) medical device milestone—if you treat timeline as an operational deliverable, not a hope. The region is not a single market: documentation, ethics review cadence, import steps, and contract mechanics vary by country and by whether your study is observational, non-significant risk (NSR), or significant risk.

    This article provides a practical way to plan an FIH device study timeline across Latin America in 2026: what workstreams to run in parallel, where delays typically occur, and how to de-risk your critical path without compromising compliance or participant safety.

    1) Start with a “workstream map,” not a single Gantt chart

    FIH device studies commonly stall because sponsors build one linear plan when the reality is a set of interdependent workstreams. A useful planning framework separates your launch into seven workstreams, each with its own owners, documents, and review cycles:

    • Protocol package (protocol, IB/IFU, risk analysis, monitoring plan, DSMB plan if needed)
    • Country regulatory submission (device classification/route, authority forms, translations, legalization requirements if any)
    • Ethics approval (central/local IRB/ethics committee workflow, consent language, recruitment materials)
    • Site contracting & budgets (CTA, indemnification, insurance certificates, payment triggers)
    • Import & logistics (shipping lanes, customs broker readiness, temp-control, labeling)
    • Site activation (SIV readiness, staff training, device accountability tools)
    • First patient in (FPI) (screening plan, recruitment levers, backup sites)

    When these workstreams are run deliberately in parallel, many sponsors can compress timelines materially versus the “submit, wait, then do the next thing” approach.

    2) A realistic 2026 timeline template (what to do in each month)

    Every program differs, but for early-feasibility or FIH device studies, a practical timeline template often looks like this:

    • Weeks 0–2: Feasibility + site shortlist. Confirm patient pool, investigator interest, imaging/lab capabilities, and whether your endpoints are standard-of-care in that setting.
    • Weeks 1–4: Submission-ready document set. Build the “country-ready” version of the protocol package: consistent terminology, device description aligned with IFU, and localized consent templates.
    • Weeks 3–8: Parallel ethics + regulatory preparation. Prepare authority-specific forms while the ethics packet is being finalized; do not wait for final contracts to start regulatory readiness.
    • Weeks 6–12: Contracts, budgets, and insurance. In many countries, the slow step is not scientific review but the negotiation of indemnification clauses, invoice rules, and insurance wording.
    • Weeks 8–14: Import and first shipment readiness. Align labeling, airway bills, and broker processes early; confirm whether your device is shipped as commercial goods, samples, or study materials and plan accordingly.
    • Weeks 12–18: SIV + site activation. Execute training, device accountability procedures, and data capture dry runs.
    • Weeks 16–24: FPI window. A strong screening plan and backup sites protect you from “approval achieved, recruitment delayed.”

    Rather than treating “approval” as the finish line, treat it as the midpoint: you still need operational readiness to reach FPI.

    3) Where timelines slip (and how to protect the critical path)

    Across Latin America, recurring delays tend to cluster into a few categories:

    • Translation and document consistency issues. Inconsistencies between protocol, IFU, and consent language trigger rework during ethics review.
    • Contract sequencing mistakes. If you wait for final CTA language before starting budget alignment or insurance certificates, you create avoidable idle time.
    • Import readiness left too late. Even when the device is low-risk, shipments can be rejected if labeling, documentation, or declared values are unclear.
    • Over-reliance on a single site. A single high-performing hospital is not a recruitment strategy; build a backup shortlist early.

    Two simple practices prevent many timeline slips: (1) run a weekly “document control” check to keep all versions synchronized, and (2) hold a pre-import readiness call with your broker and study team before any shipment is booked.

    4) Country selection: choose based on constraints, not hype

    Latin America offers multiple attractive options, but the best country for your FIH study depends on constraints:

    • Need speed? Prioritize clear ethics pathways, experienced investigators, and predictable import lanes for study materials.
    • Need specific patient phenotypes? Choose where that patient population is concentrated and where endpoints align with standard clinical practice.
    • Need imaging or specialized procedures? Ensure site infrastructure and maintenance/QA standards can support your device and endpoints.

    A practical rule: pick the country where your operational bottleneck is easiest to solve. If your bottleneck is import complexity, choose the market where your logistics and broker experience is strongest. If your bottleneck is investigator capability, choose the market with the deepest specialty network.

    FAQ

    • How long does an FIH device study typically take to reach first patient in (FPI) in Latin America?
      Many sponsors plan a 4–6 month window from kick-off to FPI when workstreams run in parallel, but timelines depend on device risk, required reviews, contracting speed, and import readiness.
    • What is the most common avoidable delay?
      Contracting and insurance language misalignment, followed closely by late import readiness and inconsistent translated documents.
    • How can sponsors reduce timeline risk without cutting corners?
      Use a workstream map, keep document versions synchronized, and build redundancy (backup sites, backup shipping lanes, and a recruitment contingency plan).

    Bottom line: In 2026, sponsors that treat Latin America FIH timelines as an integrated regulatory-and-operations program—rather than a single “submission” event—can reach FPI faster and with fewer surprises.

  • Brazil’s 90 Day Clinical Trial Review Cap: What Medtech Sponsors Should Do Before Submitting

    Brazil’s 90-Day Clinical Trial Review Cap: What MedTech Sponsors Should Do Before Submitting

    Brazil has moved from being a “high-potential but unpredictable” country for early-stage MedTech studies to a jurisdiction with a defined statutory review clock. For sponsors, that shift is not just a speed story — it is a planning story. When review timelines become shorter and more predictable, the relative impact of preventable sponsor-side errors gets larger.

    This article is written for MedTech founders, clinical operations leaders, and regulatory directors who want to run first-in-human (FIH) or early feasibility work in Brazil without losing weeks to rework. We focus on what you can control before submission: dossier readiness, ethics strategy, local operational prerequisites, and vendor orchestration.

    Why a faster regulatory clock changes the sponsor playbook

    Short timelines compress decision-making. If you used to “fix it after ANVISA feedback,” you may no longer have that luxury — because site contracts, import permits, radiology workflows, and ethics committee coordination can become the rate-limiting steps. A faster clock also forces clearer internal governance: who owns the final protocol, the risk assessment, the device technical file, and the country-specific annexes?

    Practically, the sponsor question becomes: How do we arrive at Day 0 with no missing pieces? The goal is to avoid pauses caused by translation gaps, document format mismatches, incomplete investigator packages, or unaligned device documentation.

    Pre-submission checklist: what to lock down before Day 0

    • Protocol version control: Confirm the final protocol, synopsis, schedule of assessments, and statistical plan are aligned — and that the same versions appear in every submission component.
    • Risk classification and device description: Ensure the device description, intended use, instructions for use, and risk analysis are consistent across documents. Inconsistency is one of the most common sources of questions.
    • Investigator and site packages: Collect CVs, training evidence, GCP documentation, and site capabilities early. In Brazil, the operational readiness of sites can become as important as the regulatory dossier.
    • Translations and local formatting: Build time for Portuguese localization and formatting checks. A strong translation is not only linguistic — it must preserve clinical meaning and match annex references.
    • Informed consent strategy: Prepare consent language that is clear, compliant, and aligned to local norms. If your device includes software, connectivity, or data transfer, incorporate that into consent and data handling text.
    • Import and logistics planning: Map the path for device shipment, labeling, and storage. Even for non-radioactive devices, customs, temperature needs, and distribution responsibilities can derail timelines.

    Parallel ethics + regulatory review: how to operationalize it

    When a system allows parallel tracks, the bottleneck often shifts to coordination. Sponsors should treat ethics submission as a project with its own critical path, not as an administrative afterthought. Build a unified submission calendar and align on:

    • Sequence of internal approvals: Decide who signs off on ethics content and who owns final responses.
    • Site-by-site variance: Even with a national framework, each site can introduce operational nuance. Standardize as much as possible, but plan for local adjustments.
    • Response management: Pre-write response templates for common questions (risk/benefit, recruitment strategy, device safety, data management) so you can move quickly.

    For FIH and early-stage work, ethics committees will often focus on patient protection and feasibility: training, emergency procedures, follow-up, and the practical ability of the site to manage adverse events. Your dossier should show readiness, not just compliance.

    What MedTech sponsors often underestimate in Brazil

    Speed-friendly frameworks do not eliminate complexity; they amplify the cost of under-planning. The most common underestimates include:

    • Data and privacy workflows: If your study uses digital endpoints or remote monitoring, align data flows, storage, and access controls early.
    • Device accountability: Plan how devices will be tracked, stored, returned, and reconciled. Accountability gaps create audit risk and can slow activation.
    • Training: Documented training is not optional in early-stage device studies. Build training into your timeline and capture evidence systematically.
    • Vendor interdependencies: CRO, imaging core lab, shipping/logistics, and local regulatory support must operate from the same timeline assumptions and document set.

    FAQ

    1) Does a statutory review cap guarantee approval in 90 days?
    No. A cap can improve predictability, but the practical timeline still depends on dossier quality, completeness, and how quickly questions are resolved.

    2) Should we treat Brazil as a first-choice country for FIH studies?
    Brazil can be compelling when the patient population, investigator expertise, and activation path fit the product. Sponsors should evaluate Brazil alongside other Latin American jurisdictions based on feasibility, ethics speed, and operational readiness.

    3) What’s the biggest sponsor-side mistake?
    Submitting with misaligned documents (protocol vs. device description vs. risk file) and assuming issues can be fixed “during review.” In faster systems, that approach often costs more time, not less.

    Bottom line: If your goal is to capture the benefit of a faster review framework, your work starts well before Day 0. A sponsor-side checklist — executed early — is often the difference between a fast approval and a slow cycle of preventable questions.

  • $8 Billion Of Pharma Capital Just Pointed At Argentina. What Medtech Founders Should Take From The May 29 CAEME Announcement.

    On May 29, 2026, the Cámara Argentina de Especialidades Medicinales (CAEME) announced jointly with President Javier Milei a six-year clinical research investment commitment from seven multinational pharmaceutical companies: Pfizer, Merck, Roche, Novartis, BMS, GSK, and Sanofi. The total commitment is USD 8 billion through 2032. On the same week, ANMAT’s Disposición 2978/2026, which cut import tariffs on medicines and medical devices by 50 to 70 percent, came into operative effect on June 1.

    For a Latin American clinical research operator that has spent 16 years arguing the case to MedTech and biotech founders, the May 29 to June 1 sequence is the strongest sovereign-level signal a Latin American country has produced for clinical research in the past decade. The data and the policy arrived in the same week. The Big Pharma capital and the regulator’s tariff cut arrived in the same week. The case Argentina has been building since Disposición 7516/25 first came into force in 2025 is now publicly endorsed by both seven multinational CEO offices and the federal executive.

    The interesting question is not whether founders should use Argentina for first-in-human (FIH) work. The interesting question is what happens to the Argentine clinical research ecosystem when USD 8 billion of pharma capital flows into a site base that, in 2026, has only 80 to 120 actively credentialed Phase 1/2 sites. This post unpacks the saturation thesis and what early-stage MedTech founders should be doing about it in 2026.

    The Site Saturation Math

    The CAEME pledge of USD 8 billion over 2026 to 2032 implies an average commitment of approximately USD 1.33 billion per year. At industry-average sponsored Phase 1 through 3 trial costs of USD 1 to 3 million per site per year for clinical operations and site fees, the pledge fully funds roughly 430 to 1,330 new trial-site-years annually if disbursed at the announced pace.

    Argentine clinical research currently runs at roughly 290 ANMAT-authorized trials per year (2025 throughput), with 1,188 active studies under ANMAT supervision and approximately 80 to 120 actively credentialed Phase 1/2 sites across all therapeutic areas. The pledge contemplates a 2.5x step-up in trial inflows against approximately the same site base.

    The implication is straightforward. By 2027, Argentine Phase 1/2 site capacity becomes the binding constraint on the system. Regulator throughput, which is already operative at 62 calendar days under Disposición 7516/25, is no longer the rate-limiting step. Site availability is. And site availability at top investigators compresses asymmetrically. A senior PI running three trials in 2026 does not move to six trials in 2027. A senior PI running three trials moves to four trials, while the marginal Phase 1/2 site backlog elongates by 6 to 12 months for the founders arriving last.

    Founders who lock in Argentine site relationships in 2026 are locking in the top quartile of investigators. Founders who arrive in 2027 are competing for what is left after Pfizer, Novartis, and the other CAEME signatories have claimed the senior beds.

    Why the Argentine Government Did This Now

    Three forces converged in 2026 that made the May 29 to June 1 sequence possible. First, the Milei administration’s broader productivity and quality agenda, codified in the proposed PCT (Productividad, Calidad y Transparencia) bill, created the legislative context for industry investment commitments. Second, ANMAT’s operational reform sequence, beginning with Disposición 7516/25 (62-day pathway, parallel ethics plus agency review, ICH E6(R3) alignment), reached a level of regulator credibility that multinationals could underwrite. Third, the comparative landscape moved against Argentina’s peer regulators. Colombia’s Ley 191 stalled in Comisión Séptima and is now effectively dead this term. Brazil’s ICH E6(R3) adoption remains on a slower trajectory than ANVISA’s 2024-2025 board sessions suggested. Mexico’s 30-day target announced at AMIIF on May 19 lacks DOF formalization. Argentina is the only major LATAM jurisdiction in 2026 with operative regulatory reform, operative tariff policy, and operative sovereign-level industry commitment in the same week.

    The PCT bill is the only caveat that matters. The CAEME pledge is contingent on PCT passage. As of June 1, the bill remains stalled. Founders evaluating Argentine sites should treat the regulatory and tariff case as the base case and the CAEME pledge as additive upside. Disposición 7516/25 and Disposición 2978/2026 are in force regardless.

    How to Sequence Argentina in 2026

    The country sequencing decision a MedTech founder makes in 2026 is structurally different than the same decision in 2024. Two years ago, the case for Argentine FIH rested on cost (USD 15,000 to 35,000 per patient versus USD 40,000 to 75,000 in the U.S. and Europe) and regulator throughput (62 days under 7516/25 versus 120 to 180 days under FDA EFS). Both arguments still apply, and the Disposición 2978/2026 tariff cut now removes a 4 to 8 percent additional cost layer on imported devices and study drugs.

    What is new in 2026 is the time pressure. The CAEME pledge does not change the operational case. It changes the urgency of the operational case. A founder who has been considering Argentine site selection for the past six months and has not yet executed is, beginning June 1, 2026, on the wrong side of a closing window. By Q4 2026, the same site relationships will be visibly competitive. By Q2 2027, the top-quartile PI list will be substantively claimed.

    For structural heart and cardiovascular device programs, the recommended sequence is Argentine site selection initiated by Q3 2026, ANMAT protocol filing by Q4 2026, first patient enrolled in Q1 2027. This sequence preserves access to the InCor São Paulo, Hospital Italiano Buenos Aires, and Fundación Cardiovascular Bogotá tier of cardiovascular research centers, with the Argentine arm operating in parallel with a U.S. EFS submission.

    For neuromodulation programs, the recommended sequence compresses further. Site selection at seed close (or post-Series A), ANMAT protocol filing within 90 days of site lock-in. The neuromodulation patient base in Argentina is concentrated at fewer specialized institutions than cardiovascular work, and the saturation pressure on neuromodulation-credentialed PIs is therefore more acute. Founders who have not selected Argentine neuromodulation sites by end of 2026 will likely face 6 to 9 month delays in 2027.

    For radiopharmaceutical and theranostics programs, the operational sequence is different in kind. Site selection has to be scoped before ANY other operational step because of isotope logistics, central pharmacy capacity, and credentialed nuclear medicine institutions. Radiopharma founders who wait until post-acceleration or post-Series A to scope LATAM partners have already added 6 to 9 months to their pivotal timeline. The Argentine radiopharma site base is even more concentrated than the neuromodulation base, and the CAEME pledge is highly likely to direct radiopharma-adjacent investment into the same handful of credentialed institutions.

    What This Means for the Colombia Case

    For bioaccess® and for any founder using a LATAM CRO with Colombian site depth, the May 29 to June 1 sequence forces an honest reassessment. Colombia in 2026 holds the following: established U.S.-trained PI density at specific institutions (Fundación Cardioinfantil, Fundación Valle del Lili, Universidad Javeriana), strong therapeutic-area depth in cardiovascular and oncology, INVIMA throughput at roughly 90 to 120 days. Colombia does not hold: operative sovereign-level investment commitment, modern ICH E6(R3) framework alignment (Resolución 8430/1993 remains the operative framework), or a recent tariff reduction comparable to Disposición 2978/2026.

    The Colombia case for 2026 is no longer “cheaper and faster.” The Colombia case is “specific therapeutic-area depth, U.S.-trained PI networks, and complementarity to an Argentine arm.” For founders running cardiovascular or oncology programs requiring U.S. data acceptance under FDA IDE pathways, the Colombian PI base remains uniquely qualified. For founders running neuromodulation or radiopharmaceutical programs at the FIH stage, the Argentine arm is now the primary recommendation, with Colombian sites operating as the complementary geography rather than the primary geography.

    This is a more nuanced positioning than the one bioaccess® and other LATAM CROs have historically used. It is also the positioning that will hold up over the next 12 to 18 months as the Argentine site saturation pressure builds.

    What Founders Should Do Before End of Q3 2026

    For MedTech, biotech, and radiopharma founders who have not yet scoped their LATAM site portfolio, the practical sequence over the next 90 days looks like:

    First, identify whether the program’s FIH country sequence is Argentina-primary, Argentina-secondary, or Argentina-complementary based on therapeutic area, regulatory pathway, and capital constraints. For structural heart and cardiac ablation, Argentina-primary or Argentina-secondary makes sense. For neuromodulation, Argentina-primary. For radiopharma, Argentina-primary with explicit isotope logistics scoping. For oncology devices with U.S. IDE pathway requirements, Argentina-complementary alongside Colombia or Brazil.

    Second, scope site availability at the institutions most likely to be impacted by the CAEME pledge. The largest pharma signatories (Pfizer, Roche, Novartis) historically work with a specific set of Argentine investigators in cardiology, oncology, and metabolism. Site availability at those investigators will compress first.

    Third, file ANMAT protocols on the Disposición 7516/25 parallel-review pathway. The 62-day timeline allows a 2026 Q3 site selection to produce first-patient-in by year-end. Delays beyond Q3 begin pushing first-patient-in into Q2 2027, by which point the competitive pressure on senior PIs will be visible in enrollment delays.

    Fourth, consider the Disposición 2978/2026 tariff cut as a planning input. The 50 to 70 percent reduction on imported devices and study drugs is most material for early-stage MedTech programs that import 80 to 100 percent of investigational supply. Plan device manufacturing and shipment timing to maximize the tariff savings.

    The Bottom Line

    Argentina did not become a clinical research hub on May 29, 2026. Argentina has been a clinical research hub for 30 years. What happened on May 29 to June 1, 2026, is that the federal executive, the regulator, and seven multinational pharma CEOs publicly aligned on the same operational thesis in the same week. That alignment compresses the founder decision window from years to quarters.

    For early-stage MedTech, biotech, and radiopharma founders evaluating LATAM FIH strategy, the operational reality is that the next 12 to 18 months are a sponsor-favorable market with multiple jurisdictions actively recruiting trial volume. Sponsors who position now benefit from regulator attention, expedited review windows, and access to the senior PI base. Sponsors who delay lose that window.

    The most expensive FIH decision a founder makes is not the per-patient cost of a single study. It is the calendar cost of choosing the wrong country sequence for their specific program. Argentina’s May 29 to June 1 sequence makes the calendar argument harder to ignore.

    If you are evaluating a 2026 LATAM FIH country sequencing decision and want a tailored proposal that incorporates the new ANMAT regulatory and tariff environment alongside Colombian and Brazilian complementary site options, the team at bioaccess® can produce a country-level model within two weeks. We have run FIH trials across Argentina, Colombia, Brazil, and Mexico since 2010, and our U.S. EFS plus LATAM FIH practice is the only one in Latin America structured to deliver both pathways under a single operational team.

    Citations:

  • Law 14.874/2024 Explained: How Brazil’s 90‑Business‑Day Review Window Changes Early‑Stage Clinical Trial Planning

    Law 14.874/2024 Explained: How Brazil’s 90‑Business‑Day Review Window Changes Early‑Stage Clinical Trial Planning

    For MedTech and Biopharma teams considering Latin America, Brazil has historically been seen as a high-potential but hard-to-predict jurisdiction for early-stage clinical trials. That uncertainty can inflate budgets and push teams toward smaller, single-country feasibility strategies.

    Brazil’s Law No. 14.874/2024 introduced a clear constraint: for primary petitions for clinical trials with humans (for marketing authorization purposes), the health analysis may not exceed 90 business days. The law also describes how additional information requests affect the clock.

    This article explains what the 90-business-day window means in practical terms, how sponsors can build a sponsor-ready activation timeline around it, and what pitfalls still cause delays even in a more predictable regime.

    What the law changed (and what it did not)

    The most sponsor-relevant shift is that a defined review window reduces planning ambiguity. A predictable maximum review duration enables better parallelization: ethics preparation, site contracting, and supply chain setup can be scheduled against a more reliable regulatory milestone.

    However, a legal review window does not automatically eliminate operational delays. Sponsors still need to manage:

    • Dossier completeness and consistent technical documentation
    • Ethics sequencing across institutions and committees
    • Import readiness for investigational product shipments
    • Site activation capacity (training, contracting, scheduling)

    In other words, the “clock” helps the regulatory portion of the critical path—but the rest of the program still needs a plan.

    Translating “90 business days” into an activation timeline

    Sponsors often underestimate how different business days can be from calendar days when building a global timeline. A pragmatic approach is to create three layers:

    • Regulatory layer: submission, review window, and potential information request handling
    • Ethics layer: committee submissions and approvals (often overlapping but not identical to regulatory steps)
    • Operations layer: contracts, budget approvals, training, and supply chain readiness

    A sponsor-ready planning template for Brazil should include:

    • Week 0–2: lock document ownership, finalize submission-ready dossier, confirm translation requirements, and run an internal quality check.
    • Week 2–4: submit to the relevant bodies; initiate site contracting and budget cycles in parallel.
    • During review window: implement a weekly “readiness review” covering import documentation, device labeling alignment (if applicable), training scheduling, and monitoring plans.
    • Upon clearance + ethics alignment: initiate first shipment, conduct site initiation, and begin enrollment.

    The objective is to avoid a common failure mode: regulatory clearance arrives, but operations are not ready—so the team loses the predictability advantage that the defined window provides.

    How information requests can still create delays

    Even with a defined maximum window, sponsors should plan for information requests. The practical lesson is to assume that the first submission must be as complete as possible, and that the team must be ready to respond quickly.

    To reduce the chance of delays:

    • Assign a single submission owner responsible for consistency across protocol, investigator brochure (if applicable), device dossier, and administrative documents.
    • Create a rapid-response package before submission: technical specs, risk management summaries, labeling variants, and manufacturing documentation.
    • Pre-brief sites on likely follow-up questions so responses do not stall waiting for institutional input.

    Speed matters because information requests often pause progress until the sponsor responds, and slow responses can negate the benefits of the defined review period.

    Why Brazil’s predictability matters for LATAM multi-country strategy

    For some early-stage teams, Brazil may now be easier to include in a multi-country Latin America strategy when paired with other jurisdictions. The strategic value is not only speed—it is credibility of planning. When leadership teams can explain why the timeline is realistic, financing, vendor contracting, and site commitments become easier.

    To maximize the benefit, sponsors should treat Brazil as one component of a LATAM activation architecture:

    • Define a country sequencing strategy (which country starts first and why)
    • Standardize document templates across countries (with country annexes)
    • Build a supply chain plan that can support staggered activations without stockouts

    When done well, the result is not just a faster first patient in; it is a trial program that is easier to scale.

    FAQ

    Does the 90-business-day window guarantee approval?

    No. A defined window is about timing, not outcome. Sponsors still need a complete, well-justified dossier and an operational plan that supports ethics and site readiness.

    Should early-stage sponsors wait for Brazil before activating other LATAM countries?

    Not necessarily. Many sponsors can run activities in parallel across countries. The right choice depends on device complexity, supply chain constraints, and how quickly the sponsor can support multiple site activations.

    What is the single biggest mistake sponsors make with “faster” regulatory timelines?

    Assuming that regulatory speed automatically creates operational speed. The winning approach is to use predictability to parallelize work—contracts, training, and import readiness—so the program is ready when clearance arrives.

    Bottom line: Brazil’s Law 14.874/2024 gives sponsors a more predictable planning horizon. The teams that benefit most will be the ones that treat the regulatory window as a scheduling tool—and execute the operational readiness plan in parallel.

  • Brazil’s 2025 Clinical Research Rulebook: What Early-Stage Sponsors Should Do Differently

    Brazil’s 2025 Clinical Research Rulebook: What Early-Stage Sponsors Should Do Differently

    Brazil continues to be one of the most important anchors for early-stage clinical development in Latin America, but the compliance baseline is moving. In 2026, Anvisa highlighted that Brazil’s clinical research environment has been updated through Law No. 14.874/2024 (ethical aspects of research with human beings) and the newer regulatory package RDC 945/2024 plus IN 338/2024 for clinical research supporting registration of medicines, which Anvisa notes took effect in early 2025 (Anvisa).

    For MedTech founders and regulatory directors planning first-in-human (FIH) or early pivotal work in the region, the strategic opportunity remains: access to experienced investigators, high-quality sites, and diverse patient populations. The operational requirement, however, is to design submissions, vendor oversight, and essential documentation so you can demonstrate control at any moment—especially as inspection programs mature.

    1) What changed in Brazil’s research governance—and why it matters for sponsors

    Anvisa’s 2025 activity reporting explicitly connects the new ethical law and the updated clinical research regulation to the agency’s current oversight approach (Anvisa). In parallel, Anvisa’s inspection metrics reporting emphasizes inspection readiness against GCP expectations (ICH E6 (R2) or updates) while referencing RDC 945/2024 and Law 14.874/2024 as part of the inspection framework (Anvisa).

    Practical takeaway: even when timelines are competitive, sponsors should assume that documentation quality, vendor governance, and data integrity controls will be evaluated more explicitly. This is good news for well-prepared early-stage teams: strong fundamentals can shorten back-and-forth with sites and reduce downstream remediation.

    2) A sponsor-ready timeline: how to think about “FIH speed” without compliance debt

    Internal execution experience across Latin American programs repeatedly shows that speed usually breaks down in predictable places: incomplete essential documents, misaligned responsibilities between sponsor and CRO, and late-stage changes to protocol and informed consent artifacts. Treat “speed” as a systems outcome rather than a hero effort.

    • Pre-submission (4–8 weeks): lock protocol operational feasibility, confirm investigational product/device logistics, and establish a document control plan.
    • Submission-ready package: create a single source of truth for protocol, IB/IFU (as applicable), safety reporting plan, and data handling plan.
    • Site activation: standardize training, delegation, and vendor onboarding so the first site is not a one-off build.

    Many startups underestimate that “time to first patient” is often constrained by operational readiness, not just authority review. Investing early in a repeatable activation model is one of the highest ROI moves you can make.

    3) Inspection readiness: build once, benefit for years

    Anvisa’s inspection metrics report notes its focus on inspections conducted in 2024 and 2025 and positions inspections as a tool to protect participants and data integrity (Anvisa). For early-stage sponsors, the implication is clear: build inspection readiness into your operating rhythm rather than treating it as a “phase 3 problem.”

    Start with five non-negotiables:

    • Essential document discipline: version control, signatures, and clear ownership.
    • Delegation and training: role-based training mapped to tasks; keep it auditable.
    • Deviation and CAPA workflow: define severity levels and timelines; trend issues.
    • Vendor oversight: documented qualification, KPIs, and periodic review for CROs, labs, and logistics partners.
    • Data integrity: audit trails, access controls, and reconciliation between source, eCRF, and safety database.

    4) How to operationalize this across Latin America (not just Brazil)

    Brazil is rarely the only country in a Latin America strategy. Use Brazil as the quality anchor and replicate the same operating system across additional countries. You can localize what must be localized (ethics committee formats, language, import processes), while keeping your core compliance artifacts stable.

    A useful mental model: create a regional master file (core documents, SOPs, training), plus country modules (local submissions, contracts, import permits), plus site modules (delegation, logs, training, monitoring).

    FAQ

    When did Brazil’s latest clinical research regulations take effect?
    Brazil’s updated framework referenced by Anvisa includes Law 14.874/2024 (in force since 29 Aug 2024) and RDC 945/2024 plus IN 338/2024 (effective 2 Jan 2025).

    Do these changes apply to medical devices too?
    The Anvisa updates cited relate to clinical research for registration of medicines and biologics; device sponsors should still align operational quality systems and inspection readiness to ICH GCP expectations and local ethics requirements.

    How should startups prepare for inspection readiness?
    Build inspection-ready documentation from day one: role-based training, version-controlled essential documents, delegation logs, deviation management, and vendor oversight that can be demonstrated quickly.

    Need help designing a Latin America FIH plan? bioaccess® supports sponsors with regional feasibility, activation, and execution strategies built for speed and inspection readiness.

  • Argentina Just Cut Clinical Trial Import Costs By 50 70%. Here’s What 290 Authorized Trials In 2025 Tell Founders.

    On May 19, 2026, Argentina’s National Administration of Drugs, Foods and Medical Devices (ANMAT) published Disposición 2978/2026, cutting import tariffs on medicines and medical devices by 50 to 70 percent, effective June 1, 2026. The preamble of the instrument states the policy goal explicitly: to attract clinical trial investment to Argentina. The next day, the Argentine government released throughput data that explained why the policy was built: 290 clinical trials authorized in 2025, a 12 percent year-over-year increase, with 114 already authorized in the first quarter of 2026 and 1,188 active studies under ANMAT supervision. Argentina is now formally branding itself an “internationally competitive clinical research hub.”

    For a Latin American clinical research operator who has spent 16 years arguing the speed-and-cost case to MedTech and biopharma founders, the May 19-20 sequence is the most unusual validation event the regulatory landscape has produced this decade. Most LATAM clinical research positioning is CRO marketing. Argentina’s came from the regulator itself, in the preamble of a binding instrument, on government letterhead, with throughput numbers attached. That is not the same kind of evidence as a competitive pitch deck.

    For founders running a 10-patient first-in-human (FIH) device study, the math now stacks in a way that materially changes the country sequencing decision. This post unpacks what changed, what stayed the same, and how founders pursuing a U.S. Early Feasibility Studies (EFS) plus out-of-U.S. (OUS) FIH strategy should think about Argentina in 2026.

    What Changed on May 19, 2026

    Disposición 2978/2026 is the binding instrument. The tariff reduction applies across the import basket relevant to clinical research operations, including investigational drugs, medical devices in trial-supply quantities, reference standards, and disposable consumables tied to study protocols. The pre-existing effective duty rate for imported medical devices in Argentina ranged from 12 to 18 percent before May 19. Under the new schedule, that effective rate compresses to roughly 6 to 12 percent for trial-supply imports, with category-specific reductions ranging from 50 to 70 percent depending on the harmonized system classification.

    On its own, the tariff cut is meaningful. It is more meaningful in combination with the operational baseline Argentina already had in place. Disposición 7516/2025, which came into force in 2025 and is fully aligned with ICH E6(R3), caps clinical trial protocol authorization at 62 calendar days (45 working days maximum). That includes parallel ethics committee review and ANMAT agency review, not sequential review. For comparison, the U.S. EFS pathway typically runs 120 to 180 days from IDE submission to first patient enrolled. Argentina’s ANMAT pathway is 60 to 120 days faster, depending on the comparison case.

    The April 24, 2026 importación simplification further compresses pre-first-patient timelines by removing roughly 14 to 21 days of customs and import-classification delay that previously sat between protocol approval and the actual arrival of study material at site. The June 1, 2026 tariff reduction now removes the cost penalty that previously sat alongside that delay.

    The Throughput Number Most Founders Miss

    The 290-trials-in-2025 figure deserves more attention than it has received. Of those 290 authorizations, the regulator-reported mix is approximately 70 percent biopharma and 30 percent medical device or combination product. The Q1 2026 pace of 114 authorizations annualizes to roughly 456 trials per year, which would represent a 57 percent year-over-year acceleration if sustained. Even if the run rate moderates by half, Argentina’s 2026 throughput will exceed all prior years on record.

    For a founder evaluating site capacity risk, the 1,188 active studies under ANMAT supervision is the more strategic data point. Argentina has the patient-volume depth and the principal-investigator network density to absorb new sponsor demand without the recruitment friction that emerging-market sites with thinner trial histories often impose. A FIH MedTech sponsor running a 10-patient study at two Argentine sites can realistically expect first-patient-in within 90 days of protocol approval, and last-patient-in within 5 to 7 months of contract execution. Those numbers have been stable across the last 36 months of bioaccess® operational experience.

    The Cost Math, Refreshed

    Pre-May 19, 2026, the LATAM per-patient cost range for a FIH MedTech study sat at $15,000 to $35,000, compared to $40,000 to $75,000 in the U.S. and Europe. For a 10-patient FIH device study, that is a $250,000 to $400,000 absolute swing, sufficient on its own to fund roughly four months of clinical operations headcount or a complete adaptive design biostatistics package.

    The June 1 tariff reduction does not move the per-patient labor cost. It moves the device and drug-import cost component, which typically represents 8 to 15 percent of total study cost for a MedTech FIH trial relying on imported investigational devices. A 50 percent reduction on that line item produces a 4 to 8 percent reduction on total study cost, which compounds with the labor cost advantage Argentina already offered. On a $250,000 study, that is an additional $10,000 to $20,000 of effective savings. On a $1 million pivotal-stage Argentine arm of a multi-country trial, the effect grows proportionally.

    The strategic value is not the headline savings number. It is the regulatory clarity that the tariff cut produces. Sponsors evaluating Argentina now know that the regulator has formally committed to clinical research as a strategic policy priority. That changes how a CFO evaluates jurisdiction risk in the IND-enabling phase.

    The Database Anomaly and How to Work Around It

    One operational caveat is worth flagging directly. ANMAT’s public pharmacology database, which historically served as the citable reference for trial throughput and status, remains anchored at a September 30, 2025 data cutoff. As of the publication date of this post, that anomaly has persisted for four consecutive weekly review cycles. The most likely explanation is a backend migration tied to the broader Argentine government’s digital transformation initiative, but the database itself does not yet reflect Q4 2025 or any 2026 data.

    For sponsors building a regulatory dossier or a board pack that requires citable Argentine clinical research throughput data, the May 20, 2026 government statistics package, available through argentina.gob.ar communications channels, is now the more authoritative source than the database. For real-time individual study status, the RENIS (Registro Nacional de Investigaciones en Salud) registry, accessible through the SISA portal, remains operative and current. Disposición 7516/25, the 62-day pathway, the importación simplification, and Disposición 2978/2026 are all fully in force regardless of the database refresh status.

    How to Sequence Argentina in a U.S. EFS Plus OUS FIH Strategy

    The most common 2026 founder question is whether to run U.S. EFS first, OUS FIH first, or both in parallel. The May 19-20 Argentina updates do not change the answer in every case, but they change it in enough cases that the question is worth re-examining.

    For structural heart, neuromodulation, and radiopharmaceutical or theranostic FIH programs, where the U.S. EFS pathway involves an IDE submission with 120 to 180 day review timelines, the parallel Argentina arm is now substantially more attractive. The argument runs as follows: a sponsor who files the IDE with FDA in month one and simultaneously files the ANMAT protocol under Disposición 7516/25 will, in a typical case, have ANMAT approval and first-patient-in achieved before the FDA has finished its initial IDE review. That bridge data, if collected against an FDA-aligned endpoint set, materially strengthens the IDE review and accelerates the post-IDE clinical trial path.

    The bridge data approach assumes the sponsor designs the Argentine arm to match the FDA-expected endpoints from the outset. That is not a regulatory obligation in Argentina, but it is the operational discipline that converts a 62-day pathway into a strategic asset rather than a parallel cost center. ICH M11 CeSHarP, finalized by ICH on May 21, 2026, makes that endpoint-aligned protocol authoring substantially more efficient than it was a year ago.

    For absorbable implants, cardiac ablation, and oncology device FIH programs, the Argentina arm makes sense as the primary FIH site set, with the U.S. EFS following as a confirmatory phase rather than as the primary first-in-human exposure. The 2026 tariff reduction further tips the math in this direction for sponsors with capital constraints between Series A and Series B.

    What This Means for the Latin American Clinical Research Landscape

    Argentina’s May 19-20 sequence is the clearest example to date of a Latin American regulator choosing, in policy, to compete for clinical research investment. Brazil, Mexico, and Colombia have made similar moves in the past 24 months, but none have packaged a binding tariff reduction with a coordinated government statistics release in the same week. The combination is what makes the Argentine moment unusual.

    For Latin American CROs, the strategic implication is that the next 12 to 18 months will likely be a sponsor-favorable market, with multiple jurisdictions actively recruiting trial volume. Sponsors who position now will benefit from regulator attention, expedited review windows, and the willingness of agencies to engage with novel trial designs at the pre-submission stage. Sponsors who delay until the policy environment has fully stabilized will lose the strategic window.

    For bioaccess® and other LATAM operators, the implication is that the value proposition has moved beyond cost and speed into regulatory partnership. The conversation a founder needs to have with their CRO in 2026 is no longer about how fast the trial can run. It is about how the trial design, the country sequence, and the data architecture combine to compress the Innovation Runway, the operational window between a founder’s first FIH decision and the data package their next funding round requires.

    The Bottom Line for Founders

    Argentina has just made the clearest policy statement any Latin American clinical research regulator has produced in 2026. The 62-day pathway under Disposición 7516/25 is operative. The importación simplification is in force. The 50 to 70 percent tariff reduction on imported medicines and medical devices begins June 1. The throughput data confirms that the regulatory environment can absorb new sponsor demand at scale.

    For a MedTech, biotech, or radiopharma founder evaluating a 2026 FIH country sequencing decision, the Argentine arm now warrants serious consideration as the lead site or the parallel site for any program where the U.S. EFS pathway is the comparison baseline. The most expensive FIH decision a founder makes is not the per-patient cost of a single study. It is the calendar cost of choosing the wrong study to run first. Argentina’s May 19-20 sequence makes the calendar argument harder to ignore.

    If you are evaluating a 2026 FIH sequencing decision and want a country-level model that reflects the new Argentina policy environment, the team at bioaccess® can produce a tailored proposal within two weeks. We have run FIH trials across Argentina, Colombia, Brazil, and Mexico since 2010, and our U.S. EFS plus LATAM FIH practice is the only one in Latin America structured to deliver both pathways under a single operational team.

    Citations:

  • First-In-Human In Brazil In 2026: A Practical Timeline For Sponsors

    First-in-Human in Brazil in 2026: A Practical Timeline for Sponsors

    Primary keyword: first-in-human trial Brazil timeline

    Brazil is increasingly on the shortlist for early-stage clinical development because sponsors can combine a large patient base with growing regulatory clarity. A recent policy analysis argued that Lei 14.874 de 2024 created the basis for a more predictable environment and, for the first time, establishes timelines and greater regulatory clarity for clinical studies.

    This article gives a practical, sponsor-side timeline for launching a first-in-human (FIH) study in Brazil in 2026—what to do first, what typically slows teams down, and how to sequence work so you do not lose weeks to preventable back-and-forth.

    1) Define the “Brazil-ready” FIH package (Weeks 0–2)

    Before any submission, align internal stakeholders on what “Brazil-ready” means. For most MedTech and biopharma sponsors, FIH readiness is not only a protocol question—it is also a documentation and site execution question.

    • Protocol and IB alignment: Ensure endpoints, safety monitoring, and dose-escalation logic are consistent with your global plan.
    • Country adaptations: Identify what must be localized or supplemented (consent language, site materials, labeling, and investigator documentation).
    • Feasibility assumptions: Confirm whether required imaging, lab, or procedural capabilities exist at target sites.

    Internal best practice: Create a single “FIH Brazil master checklist” with owners and due dates. Treat it as a deliverable, not an afterthought.

    2) Select sites for speed, not just prestige (Weeks 1–4)

    In FIH, startup speed is highly correlated with site readiness. Sponsors often choose sites based on reputation, then discover contracting and operational realities late.

    • Prioritize operational maturity: Look for sites with dedicated research staff, established ethics processes, and experience with sponsor audits.
    • Validate recruitment pathways: Treatment-naive populations can be an advantage, but referral networks still matter.
    • Assess import and handling constraints: If your study uses temperature-sensitive materials, confirm storage and chain-of-custody procedures early.

    3) Build a parallel workstream plan (Weeks 2–6)

    The most common timeline mistake is running tasks sequentially that can be executed in parallel. Even when formal review clocks improve, sequential execution can erase the benefit.

    To compress time, run these workstreams at the same time:

    • Regulatory dossier preparation (quality, safety documentation, and trial authorization package)
    • Ethics submission package (site-specific documents and consent)
    • Contracts and budgets (CTA, indemnities, payment schedules, and monitoring model)
    • Supply and logistics readiness (import planning, labeling, storage validation, and back-up scenarios)

    Even when legal reforms aim to improve predictability, sponsors still need coordinated execution across stakeholders to realize those gains.

    4) Anticipate “hidden” startup time: contracts, import, and training (Weeks 4–10)

    Even when review timelines are favorable, sponsors can lose time after approvals due to operational bottlenecks:

    • Contract negotiation cycles: Build buffer time for legal review, redlines, and institutional sign-off.
    • Import and release: If your investigational product or device must be imported, confirm lead times and documentation requirements early.
    • Site initiation and training: FIH trials require strict adherence to safety procedures; schedule training sessions while approvals are in progress.

    Practical tip: Maintain a “go-live readiness dashboard” that tracks contract status, shipment readiness, and training completion. This prevents surprises when the green light arrives.

    5) A sponsor-friendly 2026 FIH timeline (example)

    Every program is different, but a realistic planning template looks like this:

    • Weeks 0–2: Brazil-ready protocol package, checklist, and internal alignment
    • Weeks 1–4: Site selection, feasibility, and early budget/CTA drafts
    • Weeks 2–6: Parallel dossier + ethics package finalization
    • Weeks 4–10: Contracts, import planning, training, and vendor setup
    • Weeks 10–14: Final site activation steps and first-patient readiness

    If you are aiming for speed, measure time-to-ready as rigorously as you measure time-to-approval. In many FIH programs, the fastest sponsors are simply the ones that avoid rework.

    FAQ: First-in-human trial Brazil timeline

    • How long does it take to start a first-in-human trial in Brazil?
      Timelines vary by protocol complexity and site readiness, but sponsors should plan for parallel regulatory and ethics pathways, early document localization, and realistic contracting and import lead times.
    • What is the biggest cause of FIH delays in Brazil?
      In practice, delays often come from incomplete documentation, late site selection, and underestimated startup logistics (contracts, import permits, and investigational product readiness), not just the formal review clock.
    • Can Brazil FIH data support US or EU submissions?
      Yes, when the trial is designed to international GCP standards and endpoints align with your global regulatory strategy, Brazilian data can be part of a broader evidence package.

    Need help planning an FIH startup in Brazil or across Latin America? bioaccess® supports sponsors with country startup planning, site activation, and operational execution—without exposing confidential details publicly.

  • Brazil’s 90‑Business‑Day ANVISA Clock: How to Plan First‑in‑Human Activation Without Bottlenecks

    Brazil’s 90‑Business‑Day ANVISA Clock: How to Plan First‑in‑Human Activation Without Bottlenecks

    Brazil has moved from “unpredictable timelines” to a more clock-driven model for key clinical trial petitions. According to the U.S. NIH ClinRegs Brazil overview, Law No. 14.874 requires ANVISA’s analysis of primary petitions for clinical trials (including Clinical Drug Development Dossiers, DDCMs) to be completed within 90 business days. This is a meaningful planning advantage for MedTech and Biopharma teams designing first‑in‑human (FIH) or other early-stage studies in Latin America.

    But a defined regulator timeline does not automatically translate into a fast first-patient-in. Activation can still stall due to ethics sequencing, site contracts, import permits, labeling, budgeting, and operational readiness. The sponsors who benefit most are the ones who orchestrate the entire activation system around the review clock—not just the regulatory submission.

    This article provides a practical playbook for using Brazil’s defined review window to reduce uncertainty without compromising compliance. It is written for MedTech founders, clinical operations leaders, and regulatory directors planning early clinical evidence generation in Latin America.

    1) What the “90‑business‑day clock” means (and what it doesn’t)

    In many countries, the biggest activation challenge is not the technical content of the dossier—it is uncertainty. When timelines drift, every downstream dependency becomes harder: site selection, device logistics, vendor contracting, and financing.

    Brazil’s framework has introduced a clearer expectation. ClinRegs summarizes that ANVISA’s analysis of primary petitions for clinical trials with human beings “must be completed within 90 business days” under Law No. 14.874, with related implementing details in Resolução RDC No. 945 (including how the 90 business days are counted for DDCM/DEEC petitions).

    Important nuance: a regulator timeline is one piece of a multi-track activation pathway. If the sponsor treats the ANVISA clock as the entire schedule, they can still lose weeks or months elsewhere.

    2) Build an activation timeline like a network, not a checklist

    Fast activation is usually the result of parallelization, not heroics. A useful way to plan is to treat each workstream as a node in a network:

    • Regulatory dossier readiness (DDCM/DEEC content, translations, country-specific annexes)
    • Ethics committee readiness (Brazil CEP/CONEP strategy, submissions, anticipated questions)
    • Site readiness (feasibility, equipment, training, contracts, budgets)
    • Import and logistics readiness (customs broker, labeling, packaging, temperature control, returns)
    • Data and safety operations (eCRF build, SAE workflows, vendor setup, monitoring plan)

    In early-stage MedTech programs, the “critical path” often shifts midstream. For example, the device may be available, but site contract negotiation drags. Or the site is ready, but import documentation is incomplete. A network view helps you see what must be done in parallel so that the 90-day review window is not wasted.

    3) A practical pre-submission readiness package (what to have done before day 0)

    To benefit from predictable review windows, sponsors should aim to begin ANVISA review with minimal “churn” during the clock. In practice, this means building a readiness package before the submission date. Common elements include:

    • Protocol that is operationally executable: endpoints, visit schedule, and device handling that local sites can implement.
    • Risk-driven monitoring and safety plan: proportional to first-in-human risk, with clearly defined escalation pathways.
    • Brazil-ready informed consent: culturally appropriate language; processes for re-consent if amendments occur.
    • Import map: who will act as importer-of-record, how devices will be labeled, and the evidence trail for traceability.
    • Site contracts and budgets in draft form: so legal review does not become the gating item after regulatory clearance.

    Internal experience across Latin America shows that when sponsors plan only the submission, they often discover the “real bottleneck” later. Conversely, when they package readiness early, they can compress time-to-site-initiation after regulatory clearance.

    4) Common activation bottlenecks in Brazil (and how to design around them)

    Even with a defined regulator timeline, teams can lose time in avoidable areas. Here are recurring bottlenecks and practical ways to design around them:

    • Ethics sequencing misunderstandings: plan early for CEP/CONEP pathways and expected document sets; align translations and investigator documents up front.
    • Device logistics not protocolized: define receipt, storage, accountability, and disposal processes inside the protocol and site manuals.
    • Training delays: schedule investigator meetings and device training as soon as sites are selected; do not wait for final approvals to build training assets.
    • Budget misalignment: ensure site budgets reflect local realities (procedures, imaging, follow-up) to reduce renegotiation cycles.

    Operationally, the fastest programs are those where regulatory and operations leaders co-own the activation timeline, instead of treating it as a handoff from “regulatory” to “clinops.”

    5) How to use Brazil’s timeline advantage in a multi-country Latin America strategy

    Brazil’s defined review window can be especially valuable when used as one “anchor country” in a broader Latin America evidence strategy. Sponsors often seek to generate credible early data quickly, then expand into additional markets.

    To do this effectively:

    1. Design the protocol for exportability: align endpoints and data standards with future regulatory and reimbursement conversations.
    2. Standardize your core dossier: build a master package that can be adapted for different authorities without reinventing content.
    3. Plan the expansion pathway early: identify which countries can open in parallel (based on timelines, import complexity, and site readiness).

    For example, NIH ClinRegs indicates Peru’s INS must complete review and approval of a clinical trial application within a maximum of 30 working days, which may influence sequencing decisions depending on site availability and import readiness. The right path depends on the sponsor’s risk tolerance, funding timeline, and clinical endpoints.

    FAQ: Brazil’s ANVISA clock and first‑in‑human planning

    How long does ANVISA have to review key clinical trial petitions in Brazil?

    NIH ClinRegs summarizes that, under Law No. 14.874, ANVISA’s analysis of primary petitions for clinical trials (including DDCMs) must be completed within 90 business days.

    Does a 90-business-day regulator timeline guarantee fast first-patient-in?

    No. Activation speed depends on the entire system: ethics reviews, site contracts, import logistics, training, and operational readiness. A defined review window reduces uncertainty, but sponsors still need parallel planning.

    What is the biggest mistake sponsors make when planning first‑in‑human studies in Brazil?

    Treating regulatory submission as the whole project. The most common failure mode is not “regulatory delay”—it is downstream operational bottlenecks that were not designed into the timeline.

    Bottom line: Brazil’s defined review timeline can be a real advantage for early-stage programs, but only if sponsors plan activation as a coordinated set of parallel workstreams. If you treat the 90-day clock as a project management tool—not just a legal detail—you can reduce uncertainty and protect your first-patient-in date.

  • Ophthalmic First-In-Human Studies In Latin America: Why Smaller Markets Often Move Fastest

    Ophthalmic First-in-Human Studies in Latin America: Why Smaller Markets Often Move Fastest

    For ophthalmic medical device founders running their first-in-human (FIH) program — intravitreal injectors, glaucoma microshunts, retinal delivery platforms, intraocular lens innovations — the conventional wisdom says you go to a country with the largest patient pool and the most prestigious eye institutes. In Latin America, that usually points sponsors toward Mexico or Brazil first.

    That instinct is right for pivotal studies. For an FIH or early-feasibility study with 5 to 15 patients, however, our operational experience consistently shows a different pattern: smaller markets like El Salvador, Panama, and the Dominican Republic often deliver a faster path to first patient in. Here is why, and how to think about country selection for an ophthalmic FIH program.

    The FIH Math Is Different from the Pivotal Math

    Pivotal studies select for patient pool depth, statistical power, and reimbursement signal. FIH studies select for something else entirely: speed to first dose, regulatory predictability, and quality of investigator engagement on a small handful of patients.

    For a 10-patient ophthalmic FIH study, the binding constraint is rarely “are there enough eligible patients in the country” — almost any LATAM country has thousands of glaucoma, AMD, or refractive candidates. The binding constraints are:

    • Time from sponsor decision to first ethics committee submission
    • Time from EC approval to first patient screened
    • Investigator focus and availability across the dosing window
    • Regulatory predictability for a novel device class

    On all four, smaller markets often outperform the regional giants for FIH-stage work.

    Why Smaller Markets Move Faster on Ophthalmic FIH

    Three structural factors explain it.

    1. Lighter EC and regulatory queues. An ethics committee at a leading eye hospital in El Salvador or Panama might review three to six device protocols per quarter. The equivalent committee at a top São Paulo or Mexico City institute might be working through 30 to 60. Both are competent and rigorous; one simply has more capacity for a fast-track FIH protocol.

    2. Concentrated investigator attention. In smaller markets, a leading ophthalmologist running an FIH study is not splitting attention across 12 simultaneous trials. The principal investigator has direct line of sight on every screening visit, every dosing event, every follow-up — the kind of operational intimacy that materially reduces protocol deviations and data queries on a small-N study.

    3. Tighter sponsor-to-site communication. Smaller hospital systems mean fewer layers between sponsor, CRO, principal investigator, and ethics coordinator. A protocol clarification that takes a week to circulate at a large academic center can be resolved in a 30-minute call in a smaller setting.

    What This Looks Like in Practice for an Ophthalmic FIH

    For an intravitreal device, glaucoma microshunt, or refractive implant FIH program, a well-structured small-market approach typically looks like this:

    • Single-country FIH (5–10 patients). Concentrate enrollment at one or two specialized eye centers in a smaller market. Optimize for speed and data quality, not geographic diversity.
    • Validated translation and regulatory packets ready before EC submission. Smaller markets are fast on substance but unforgiving on document inconsistency.
    • Compressed feasibility-to-FPI window. A 6 to 8 week target from sponsor go-decision to first patient enrolled is achievable when site, EC, and country regulator are aligned from day one.
    • Clean handoff to a multi-country pivotal. Once FIH safety data is in hand, the pivotal can move to Mexico, Brazil, Argentina, or a multi-country footprint with the FIH evidence already supporting site selection conversations.

    When the Conventional Path Still Wins

    Smaller markets are not the right choice for every ophthalmic FIH. Three situations argue for going to Mexico or Brazil first:

    • Genetic ophthalmic indications where a specific sub-population is concentrated in one large country.
    • Complex imaging endpoints requiring a specific OCT, ultra-widefield imaging, or AI-assisted analysis platform that is only operational at a handful of large academic centers in the region.
    • Founder-led key opinion leader strategy where the FIH publication-to-investor narrative depends on a specific principal investigator’s involvement.

    For most early-stage ophthalmic device sponsors, however, the speed advantage of smaller markets at the FIH stage translates directly into reduced cash burn during the most capital-fragile window of the company’s life. In an industry where 90% of MedTech startups fail because they run out of capital before generating clinical evidence, that compression matters.

    Frequently Asked Questions

    How quickly can a well-designed ophthalmic FIH actually start in a smaller LATAM market?
    With prepared documents, an experienced site, and a clear regulatory pathway, 6 to 10 weeks from contract signature to first patient screened is realistic. The variability comes from how prepared the sponsor’s regulatory packet is, not from the country’s regulatory speed.

    Will FDA accept FIH data from El Salvador, Panama, or the Dominican Republic?
    Yes, under 21 CFR 812.28, provided the study is conducted in compliance with ICH-GCP. The FDA does not maintain a country whitelist; it evaluates each study on the quality of its execution, documentation, and ethics oversight.

    Should we run the FIH in a smaller market and then move the pivotal to Brazil or Mexico?
    This is a common and effective sequencing strategy for ophthalmic device programs. Smaller markets optimize for speed at the FIH stage. Larger markets optimize for enrollment depth, infrastructure, and regulatory signal at the pivotal stage. Designing the FIH protocol with the eventual pivotal in mind — same imaging modalities, same primary endpoint definitions, same data capture standards — makes the transition seamless.

    bioaccess® is the world’s only contract research organization built exclusively for first-in-human medical device trials, operating across 10 Latin American countries. Explore the FIH playbook at bioaccessla.com or estimate a study at bioaccessla.com/clinical-trial-calculator.